Bristol Myers Squibb Delays Alzheimer’s Psychosis Drug Readout, Extending Unmet Need
"The delay in Bristol Myers Squibb’s Cobenfy trials for Alzheimer’s disease psychosis pushes potential treatment further out, highlighting a significant unmet medical need and the challenging landscape of managing these…